Date: 2016-12-05
Type of information: Services contract
Compound: Provantage® End-to-End services
Company: Acticor Biotech (France) Merck KGaA (Germany)
Therapeutic area: Technology - Services
Type agreement: services contract
Action mechanism: Provantage® End-to-End solution is a comprehensive suite of products and services enabling biopharmaceutical companies to accelerate progress of molecules into the clinic and toward commercialization. Merck’s Provantage® End-to-End solution addresses key challenges for biopharmaceutical companies at all life cycle stages in any
geography, including established biopharmaceutical companies decentralizing manufacturing that must rapidly and efficiently establish local production capabilities. With an end-to-end approach, Merck can facilitate and accelerate
transfer of an entire process to a new location. Early-stage companies with limited manufacturing capabilities, resources and infrastructure benefit from a partner with best-in-class unit operations and the support and expertise to develop processes and production facilities.
Disease:
Details: * On December 5, 2016, Merck KGaA announced that it will provide its Provantage® End-to-End services
to Acticor Biotech for accelerated development and manufacturing of Acticor’s antibody fragment used for the primary treatment of ischemic stroke. The turnkey package includes process development, cGMP clinical manufacturing, quality and regulatory support, training, commercial facilities design, engineering and build-up as well as production equipment supply and process technical transfer activities.
Acticor Biotech is developing ACT-017, a humanized antibody fragment (Fab). The therapeutic candidate is
directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT-017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological hemostasis. This limits the bleeding risk associated with its inhibition. Acticor Biotech is built upon expertise and results of researches conducted by the founders: Dr. Martine Jandrot-Perrus and Dr Christian Gachet, in two INSERM units, and Professor Philippe Billiald at Paris-Sud University.
Financial terms:
Latest news:
